Many laboratories have switched from polyclonal to better-performing (for adenocarcinoma applications) monoclonal PAX8 antibodies, the latter of which are non-reactive in pancreatic NETs (i.e., polyclonal PAX8-positivity in pNETs is due to cross-reactivity with PAX6). Here, PAX8 is linked to adenocarcinoma.